Recursion Pharmaceuticals, Inc.
3.215USD
-0.2250 (-6.54%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.23▲ | $-0.23 | 2 | 1 |
| Next quarter | $-0.22▲ | $-0.22 | 2 | 1 |
| Current year | $-0.92▼ | $-0.92 | 3 | 2 |
| Next year | $-0.89▼ | $-0.88 | 3 | 4 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.23 | $-0.25 | -0.02 (-6.8%) |
| 2026-03-31 | $-0.26 | $-0.22 | +0.04 (+14.4%) |
| 2025-12-31 | $-0.32 | $-0.21 | +0.11 (+33.3%) |
| 2025-09-30 | $-0.38 | $-0.36 | +0.02 (+5.7%) |
63 ratings from 11 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Equal-Weight | $5 $5.5 | May 14, 2026 |
| Needham | Reiterated | Buy | $8 | May 7, 2026 |
| JP Morgan | Maintained | Overweight | $11 $10 | Apr 30, 2026 |
| B of A Securities | Maintained | Neutral | $7 $6 | Feb 26, 2026 |
| Needham | Reiterated | Buy | $8 | Feb 26, 2026 |
| JP Morgan | Upgraded from Neutral | Overweight | $10 $11 | Dec 17, 2025 |
| Needham | Reiterated | Buy | $8 | Sep 11, 2025 |
| Needham | Reiterated | Buy | $8 | Jul 8, 2025 |
| Morgan Stanley | Maintained | Equal-Weight | $8 $5 | Jun 16, 2025 |
| Needham | Maintained | Buy | $11 $8 | May 6, 2025 |
| Morgan Stanley | Maintained | Equal-Weight | $10 $8 | Apr 10, 2025 |
| Needham | Reiterated | Buy | $11 | Apr 8, 2025 |
| Leerink Partners | Maintained | Market Perform | $7 $6 | Feb 28, 2025 |
| Needham | Reiterated | Buy | $11 | Feb 6, 2025 |
| Keybanc | Maintained | Overweight | $12 $10 | Jan 8, 2025 |
| Needham | Reiterated | Buy | $11 | Dec 11, 2024 |
| Needham | Reiterated | Buy | $11 | Nov 20, 2024 |
| Needham | Reiterated | Buy | $11 | Nov 7, 2024 |
| Needham | Maintained | Buy | $16 $11 | Sep 4, 2024 |
| Jefferies | Maintained | Hold | $8 $6 | Sep 3, 2024 |
| Leerink Partners | Maintained | Market Perform | $9 $8 | Sep 3, 2024 |
| Needham | Maintained | Buy | $17 $16 | Aug 9, 2024 |
| Keybanc | Maintained | Overweight | $16 $12 | Jul 11, 2024 |
| Needham | Reiterated | Buy | $17 | Jun 25, 2024 |
| Needham | Reiterated | Buy | $17 | May 10, 2024 |
151 filings from 14 insiders · 20 buy / 17 sell over 6m
Officers and directors of RXRX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Borgeson BlakeDirector | Sell | 30.0k | $3.34 | $100k | Sep 1, 2026 |
| BORGESON BLAKE CHARLESDirector | Sell | 30.0k | $3.25 | $98k | Aug 4, 2026 |
| BORGESON BLAKE CHARLESDirector | Sell | 40.0k | $3.96 | $159k | Jul 7, 2026 |
| LI DEAN YDirector | Grant | 3.7k | — | — | Jul 1, 2026 |
| DAR ZAVAINDirector | Grant | 5.1k | — | — | Jul 1, 2026 |
| BUMPUS NAMANDJE N.Director | Sell | 4.0k | $3.18 | $13k | Jun 18, 2026 |
| MICHOR FRANZISKA PH.D.Director | Grant | 88.4k | — | — | Jun 17, 2026 |
| BUMPUS NAMANDJE N.Director | Grant | 88.4k | — | — | Jun 17, 2026 |
| HERSHBERG ROBERT MDirector | Grant | 88.4k | — | — | Jun 17, 2026 |
| SUN ELAINE DDirector | Grant | 88.4k | — | — | Jun 17, 2026 |
| LI DEAN YDirector | Grant | 88.4k | — | — | Jun 17, 2026 |
| BORGESON BLAKE CHARLESDirector | Grant | 88.4k | — | — | Jun 17, 2026 |
| DAR ZAVAINDirector | Grant | 88.4k | — | — | Jun 17, 2026 |
| GIBSON CHRISTOPHER C.Director | Other | 40.0k | — | — | Jun 5, 2026 |
| GIBSON CHRISTOPHER C.Director | Sell | 40.0k | $3.62 | $145k | Jun 5, 2026 |
| KHAN NAJATChief Executive Officer | Sell | 23.6k | $3.58 | $84k | Jun 5, 2026 |
| BUMPUS NAMANDJE N.Director | Sell | 4.4k | $3.54 | $16k | Jun 3, 2026 |
| BORGESON BLAKE CHARLESDirector | Sell | 30.0k | $3.68 | $110k | Jun 2, 2026 |
| GIBSON CHRISTOPHER C.Director | Other | 40.0k | — | — | May 22, 2026 |
| GIBSON CHRISTOPHER C.Director | Sell | 40.0k | $3.08 | $123k | May 22, 2026 |
No analyst notes on RXRX yet.
Analyst Ratings
6 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 1 | 4 | 0 | 0 | Buy2.29 |
| 1 mo ago | 2 | 1 | 4 | 0 | 0 | Buy2.29 |